FebriDx
Total Payments
$737,073
Transactions
63
Doctors
2
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $18,540 | 3 | 1 |
| 2022 | $1,109 | 1 | 0 |
| 2020 | $639,709 | 49 | 1 |
| 2019 | $38,715 | 6 | 0 |
| 2017 | $39,000 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $733,134 | 61 | 99.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,000 | 1 | 0.4% |
| Travel and Lodging | $939.56 | 1 | 0.1% |
Payments by Type
Research
$733,134
61 transactions
General
$3,940
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FebriDx | Rapid Pathogen Screening, Inc. | $718,534 | 1 |
| CLP-0018- FebriDx Usability Validation Study Protocol | Lumos Diagnostics, Inc. | $14,600 | 0 |
Ad
Manufacturing Companies
- Rapid Pathogen Screening, Inc. $718,534
- Lumos Diagnostics, Inc. $18,540
Product Information
- Type Device
- Total Payments $737,073
- Total Doctors 2
- Transactions 63
About FebriDx
FebriDx is a device associated with $737,073 in payments to 2 healthcare providers, recorded across 63 transactions in the CMS Open Payments database. The primary manufacturer is Rapid Pathogen Screening, Inc..
Payment data is available from 2017 to 2024. In 2024, $18,540 was paid across 3 transactions to 1 doctors.
The most common payment nature for FebriDx is "Unspecified" ($733,134, 99.5% of total).
FebriDx is associated with 2 research studies, including "FebriDx" ($718,534).